METastasis Reporting and Data System for Prostate Cancer as a Prognostic Imaging Marker in Castration-resistant Prostate Cancer
METastasis Reporting and Data System for Prostate Cancer as a Prognostic Imaging Marker in Castration-resistant Prostate Cancer
复制标题
DOI：
10.1016/j.clgc.2019.12.010
复制
发表时间：
2020-08-01
影响因子：
3.2
通讯作者：
Fujii, Yasuhisa
中科院分区：
文献类型：
--
作者：
Yoshida, Soichiro;Takahara, Taro;Fujii, Yasuhisa
全身弥散加权磁共振成像可反映骨内和骨外病变的治疗反应，其信号可反映去势抵抗性前列腺癌转移灶的活动性。全身弥散加权磁共振成像前列腺癌METastasis报告和数据系统评分有利于评估去势抵抗性前列腺癌的预后。背景：前列腺癌转移报告和数据系统（MET-RADS-P）已被提议作为全身弥散加权磁共振成像（WB-DWI）的数据采集和解释标准在晚期前列腺癌患者中进行。本研究的目的是证明去势抵抗性前列腺癌（CRPC）评分的临床意义。材料与方法：我们回顾性评价了2014年至2017年期间72例CRPC患者的WB-DWI，当时在开始新的抗癌治疗时怀疑疾病进展。分别有25例（35%）和30例（42%）患者的治疗史包括基于紫杉烷的化疗和新型激素药物。结果如下：在60例患者中确定了活动性骨转移（83%;骨转移数量= 0、1 - 2、3 - 5、6 - 10和> 10：分别为n = 12 [17%]、20 [28%]、11 [15%]、1 [1%]和28 [39%]）。进行性淋巴结转移10例（14%），内脏转移4例（6%）。在24个月的中位随访期间，36例（50%）死于前列腺癌。根据骨转移负荷和内脏转移的MET-RADS-P评分，癌症特异性生存率（CSS）显著分层（P <0.0001）。多变量分析显示，高骨转移负荷（> 10）和内脏转移的存在是较短CSS的重要指标（分别为P = 0.0036和P = 0.0017）。结论：WB-DWI上骨转移的范围和内脏转移的存在与CRPC的CSS较短相关。MET-RADS-P评分可作为CRPC的预后影像学生物标志物。(C)2019爱思唯尔公司All rights reserved.
Whole-body diffusion-weighted magnetic resonance imaging reflects therapeutic response of osseous and extra-osseous lesions, and the signal may reflect the activity of metastatic lesions of castration-resistant prostate cancer. METastasis Reporting and Data System for Prostate Cancer score of whole-body diffusion-weighted magnetic resonance imaging is advantageous to assess the prognosis for castration-resistant prostate cancer.Background: METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P) has been proposed as a standard of data acquisition and interpretation for whole-body diffusion-weighted magnetic resonance imaging (WB-DWI) performed in men with advanced prostate cancer. The aim of this study is to demonstrate the clinical significance of the scores in castration-resistant prostate cancer (CRPC). Materials and Methods: We retrospectively evaluated WB-DWI obtained from 72 patients with CRPC between 2014 and 2017, when disease progression was suspected at the time of starting a new line of anticancer therapy. Twenty-five (35%) and 30 (42%) patients had a treatment history that included taxane-based chemotherapy and new hormonal drugs, respectively. Results: Active bone metastases were identified in 60 patients (83%; number of bone metastasis = 0, 1-2, 3-5, 6-10, and > 10: n = 12 [17%], 20 [28%], 11 [15%], 1 [1%], and 28 [39%], respectively). Progressive lymph node and visceral metastases were identified in 10 (14%) and 4 (6%), respectively. During the median follow-up period of 24 months, 36 (50%) died of prostate cancer. Cancer-specific survival (CSS) was significantly stratified according to the MET-RADS-P scores of osseous metastatic burden and the presence of visceral metastasis (P < .0001). Multivariate analysis revealed that high osseous metastatic burden (> 10) and the presence of visceral metastasis were significant indicators of shorter CSS (P = .0036 and P = .0017, respectively). Conclusions: The extent of bone metastasis and the presence of visceral metastasis on WB-DWI were associated with a shorter CSS in CRPC. MET-RADS-P score can be a prognostic imaging biomarker for CRPC. (C) 2019 Elsevier Inc. All rights reserved.